

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 12, 2008

**PRESSURE BIOSCIENCES, INC.**

---

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

---

(State or Other Jurisdiction of Incorporation)

0-21615

---

(Commission File Number)

04-2652826

---

(IRS Employer Identification No.)

14 Norfolk Avenue, South Easton, MA

---

(Address of Principal Executive Offices)

02375

---

(Zip Code)

(508) 230-1828

---

(Registrant's Telephone Number, Including Area Code)

321 Manley Street, West Bridgewater, MA 02379

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 2.02 Results of Operations and Financial Condition**

On March 12, 2008, the Company issued a press release announcing its financial results for the year ended December 31, 2007. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

*Limitation on Incorporation by Reference.* The information furnished in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

*Cautionary Note Regarding Forward-Looking Statements.* Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	Press release dated March 12, 2008 of Pressure BioSciences, Inc. announcing its financial results for the year ended December 31, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 12, 2008

**PRESSURE BIOSCIENCES, INC.**

By: /s/ Edward H. Myles

---

Edward H. Myles,  
Senior Vice President of Finance and  
Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	Press release dated March 12, 2008 of Pressure BioSciences, Inc. announcing its financial results for the year ended December 31, 2007.

---

**FOR IMMEDIATE RELEASE**

**Investor Contacts:**

Richard T. Schumacher, President & CEO  
Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.  
(508) 230-1828 (T)

**Pressure BioSciences, Inc. Reports 2007 Financial Results and  
Provides Business Update**

South Easton, MA, March 12, 2008 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO - News) ("PBI") today announced that total revenue for 2007 was \$645,870 compared to \$210,289 for 2006. Revenue from the sale of PCT products and services was \$399,787 for the year as compared to \$210,289 for the prior year. This increase in revenue from PCT products and services was primarily the result of the number of installations of the Company's PCT Sample Preparation Systems ("PCT Systems") - the total number of PCT Systems installed during 2007 was twenty, as compared to eight in 2006. Also contributing to this increase in revenue was an increase in the number of PULSE Tubes and ProteoSolve-LRS Kits sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded \$246,083 of grant revenue during 2007. There was no grant revenue recognized during 2006.

As of December 31, 2007, the Company had cash and cash equivalents of approximately \$5.4 million, as compared to approximately \$5.3 million on December 31, 2006. Edward H. Myles, Senior Vice President of Finance and CFO commented: "During 2007, we effectively financed the continued development and initial commercialization of PCT with proceeds received from the liquidation of our investment in Panacos Pharmaceuticals common stock, the divestiture of Source Scientific LLC, and the sale of 126,750 shares of our common stock in our private placement completed in November 2007."

Mr. Myles continued: "Our installation of twenty PCT Systems represents a significant increase compared to the prior year. These installations came in the form of sales, leases, and rental agreements. Furthermore, included in our 2007 revenue was the sale of several of our recently launched Barocyler NEP2320 units, which have a price of approximately one half of the Barocyler NEP3229. Consistent with our strategy, we are working to drive our installed base of PCT Sample Preparation Systems so that we can continue to realize increases in our recurring revenue streams from PULSE Tubes, ProteoSolve-LRS Kits, and extended service contracts."

Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. said: "We are proud of the accomplishments of 2007 and believe that these accomplishments position us well for success in 2008. On the sales and marketing front, we have completed the hiring of seven experienced, US-based, Regional Sales Directors. Through the efforts of our marketing department, we have increased the number of leads in the US by over 2,000, and we expect that our new Regional Sales Directors will contact many of them during 2008. We also are ahead of schedule in building our international distribution network as we now have distribution agreements with three partners covering France, Switzerland, Belgium, Japan, and Korea."



**Pressure BioSciences, Inc.**  
14 Norfolk Avenue, South Easton, MA  
02375  
TEL 508-230-1828 · FAX 508-230-1829  
[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

---

Mr. Schumacher continued: "On the research and development side of the business, our accomplishments are numerous: in Engineering R&D, we drove the Barocycler NEP2320 from concept to prototype to product launch in less than a year, and in Applications R&D, we drove our ProteoSolve-LRS Kit from discovery to patent filing to scientific meeting presentation to product launch in less than eight months. In addition, in December 2007, we were awarded the prestigious Frost and Sullivan Innovation Research Award for the development of ProteoSolve-LRS."

Mr. Schumacher concluded: "We look to 2008 as the year that all of the ingredients for success may come together. We have revolutionary technology, a newly hired but experienced sales force, product in inventory, and a potential universe of approximately 390,000 scientists worldwide who might benefit from the advantages of the PCT Sample Preparation System. I am very proud of the progress that we've made in the three short years since we became Pressure BioSciences, I would like to compliment all of our employees for their hard work and dedication to date, and I would like to thank all of our shareholders for their past and continued support."

#### **About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnosics, and protein purification.

#### **Financial Teleconference and Web-cast**

As announced on March 6, 2008, the Company will host a teleconference at 4:30 pm EDST on Wednesday March 12, 2008 to discuss its 2007 financial results and to provide a business update.

To attend this teleconference via web-cast, please go to the Company's website: [www.pressurebiosciences.com](http://www.pressurebiosciences.com).

To attend this teleconference via telephone, please dial:  
(800) 909-5202  
Participant code: 4382794

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through April 4, 2008, and will be accessible through the Company's website. To access the replay, please dial (888) 203-1112 and enter code 4382794.

#### **Forward Looking Statements**

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the Company's expectations for 2008, including the potential for additional installations of PCT Systems, increased revenues from such installations, the sale of PULSE Tubes, ProteoSolve-LRS Kits and extended service contracts, the ability to convert leads into sales, leases or rental of the PCT System, the ability to continue to develop an international distribution network, the number of scientists who might benefit from the PCT Sample Preparation System, the anticipated quality and benefits of the Company's products, and beliefs regarding the validation of the Company's business plan due to the Company's growing installed base of PCT Systems. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; the Company's financial results for the fiscal year ended December 31, 2007 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customers needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen cost increases; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company's new external sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; and the Company may be unable to develop new PCT-related products that are perceived by potential customers as having advantages over current technologies and techniques. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>



Pressure BioSciences, Inc.  
14 Norfolk Avenue, South Easton, MA  
02375  
TEL 508-230-1828 · FAX 508-230-1829  
[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

**Consolidated Balance Sheets**

	<u>December 31,</u>	
	<u>2007</u>	<u>2006</u>
<u>ASSETS</u>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 5,424,486	\$ 5,335,282
Accounts receivable	118,471	37,495
Inventories	172,548	19,658
Deposits	553,483	175,300
Prepaid income taxes	56,863	38,687
Income tax receivable	249,541	710,013
Prepaid expenses and other current assets	94,783	71,476
Investments in marketable securities	-	2,060,875
<b>Total current assets</b>	<u>6,670,175</u>	<u>8,448,786</u>
<b>PROPERTY AND EQUIPMENT, NET</b>	<u>257,797</u>	<u>207,696</u>
<b>OTHER ASSETS</b>		
Intangible assets, net	328,290	376,922
Assets of discontinued operation	-	1,420,996
<b>Total other assets</b>	<u>328,290</u>	<u>1,797,918</u>
<b>TOTAL ASSETS</b>	<u>\$ 7,256,262</u>	<u>\$ 10,454,400</u>
<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 152,729	\$ 174,289
Accrued employee compensation	377,190	242,497
Accrued professional fees and other expenses	186,840	150,978
Income taxes payable	4,519	45,962
Deferred taxes	-	669,520
Deferred revenue	15,075	4,099
<b>Total current liabilities</b>	<u>736,353</u>	<u>1,287,345</u>
<b>LONG TERM LIABILITIES</b>		
Deferred revenue	6,767	9,126
Liabilities of discontinued operation	-	1,042,493
<b>Total long term liabilities</b>	<u>6,767</u>	<u>1,051,619</u>
<b>TOTAL LIABILITIES</b>	<u>743,120</u>	<u>2,338,964</u>
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>STOCKHOLDERS' EQUITY</b>		
Preferred stock; 1,000,000 shares authorized; 0 outstanding	-	-
Common stock, \$.01 par value; 20,000,000 shares authorized; 2,192,175 and 2,065,425 shares issued and outstanding	21,922	20,654
Additional paid-in capital	6,284,616	5,347,641
Accumulated other comprehensive income	-	1,384,876
Retained earnings	206,604	1,362,265
<b>Total stockholders' equity</b>	<u>6,513,142</u>	<u>8,115,436</u>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<u>\$ 7,256,262</u>	<u>\$ 10,454,400</u>





02375  
TEL 508-230-1828 · FAX 508-230-1829  
[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

**Consolidated Statements of Operations**

	<b>For the Year Ended</b>	
	<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>
<b>REVENUE:</b>		
PCT Products, services, other	\$ 399,787	\$ 210,289
Grant revenue	246,083	-
<b>Total revenue</b>	<b>645,870</b>	<b>210,289</b>
<b>COSTS AND EXPENSES:</b>		
Cost of PCT products and services	209,050	165,233
Research and development	2,022,730	1,429,711
Selling and marketing	1,386,519	528,265
General and administrative	2,174,739	2,145,196
<b>Total operating costs and expenses</b>	<b>5,793,038</b>	<b>4,268,405</b>
<b>Operating loss from continuing operations</b>	<b>(5,147,168)</b>	<b>(4,058,116)</b>
<b>OTHER INCOME:</b>		
Realized gain on securities available for sale	2,028,720	517,938
Interest income	286,600	381,713
<b>Total other income</b>	<b>2,315,320</b>	<b>899,651</b>
Loss from continuing operations before income taxes	(2,831,848)	(3,158,465)
Income tax benefit from continuing operations	520,214	745,354
<b>Loss from continuing operations</b>	<b>(2,311,634)</b>	<b>(2,413,111)</b>
<b>DISCONTINUED OPERATIONS:</b>		
Gain on sale of net assets related to discontinued operations (net of income tax of \$218,060)	1,155,973	-
<b>Net loss</b>	<b>\$ (1,155,661)</b>	<b>\$ (2,413,111)</b>
<b>Loss per share from continuing operations - basic and diluted</b>	<b>\$ (1.11)</b>	<b>\$ (1.01)</b>
Income per share from discontinued operations - basic and diluted	0.55	-
<b>Net loss per share - basic and diluted</b>	<b>\$ (0.56)</b>	<b>\$ (1.01)</b>
<b>Weighted average number of shares used to calculate income (loss) per share - basic and diluted</b>	<b>2,078,657</b>	<b>2,396,077</b>

**Investor Contacts:**

Richard T. Schumacher, President & CEO  
Edward H. Myles, Senior Vice President of Finance & CFO  
Pressure BioSciences, Inc.  
(T) 508-230-1828



Pressure BioSciences, Inc.  
14 Norfolk Avenue, South Easton, MA  
02375  
TEL 508-230-1828 · FAX 508-230-1829  
www.pressurebiosciences.com

